Stem cell–derived secretome may offer an alternative to live cell therapies for chronic wound healing
This is a narrative review examining the potential of stem cell–derived secretome as an alternative to live cell therapies for chronic wounds, including diabetic ulcers, venous leg ulcers, and pressure ulcers. The authors synthesize existing literature to argue that secretome may offer a safer, more practical option than live cell transplantation, though they do not report pooled effect sizes or comparative trial data. The review notes that direct evidence comparing secretome to live cell therapies is limited and that key outcomes such as efficacy and safety are not quantified in the available literature. Gaps include the lack of reported sample sizes, follow-up durations, and adverse event rates, which constrain definitive conclusions. The authors emphasize that secretome therapy remains an emerging approach, and its clinical role requires further validation through controlled studies. Practice relevance is not reported, and clinicians should interpret these findings as hypothesis-generating rather than practice-changing.